Trial of Pimasertib in Hematological Malignancies

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1)

Conditions

Leukemia, Myeloid, Acute
Hematologic Neoplasms

Interventions

DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib

Sponsor

EMD Serono